Aliskiren and l-arginine treatments restore depressed baroreflex sensitivity and decrease oxidative stress in...

Area of Science:

• Cardiovascular Research
• Hypertension Pathophysiology
• Pharmacology

Background:

• Renovascular hypertension involves elevated angiotensin II, oxidative stress, and endothelial dysfunction.
• Baroreflex sensitivity is impaired in this condition.
• Current treatments may not fully address these underlying mechanisms.

Purpose of the Study:

• To investigate the effects of aliskiren (ALSK) and l-arginine (l-ARG) on baroreflex sensitivity and oxidative stress.
• To evaluate their efficacy in a rat model of renovascular hypertension.
• To determine if combined therapy offers synergistic benefits.

Main Methods:

• Hypertension induced via left renal artery clipping in rats.
• Five experimental groups: SHAM, 2K1C, 2K1C+ALSK, 2K1C+l-ARG, 2K1C+ALSK+l-ARG.
• Arterial pressure, left ventricular hypertrophy, and baroreflex sensitivity assessed after 21 days.

Main Results:

• Combined ALSK+l-ARG normalized arterial pressure (108.8±2.8 mmHg).
• l-ARG and ALSK+l-ARG prevented left ventricular hypertrophy.
• All treatments restored baroreflex sensitivity; TEMPOL also improved it acutely.
• All treatments increased antioxidant and reduced oxidative pathways.

Conclusions:

• Aliskiren or l-arginine monotherapy reduces oxidative stress and restores baroreflex sensitivity in renovascular hypertension.
• Combined aliskiren and l-arginine therapy normalizes blood pressure and reverses left ventricular hypertrophy.
• These findings highlight the potential of combination therapy for renovascular hypertension.